Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?
BMC Medicine, January 2013
Michel de Lorgeril, Patricia Salen, Pascal Defaye, Mikael Rabaeus
Early randomized controlled trials (RCTs) demonstrated the health benefits of omega-3 fatty acids (n-3), whereas recent RCTs were negative. We now address the issue, focusing on the temporal changes having occurred: most patients in recent RCTs are no longer n-3 deficient and the vast majority are now treated with statins. Recent RCTs testing n-3 against arrhythmias suggest that n-3 reduce the risk only in patients not taking a statin. Other recent RCTs in secondary prevention were negative although, in a post-hoc analysis separating statin users and non-users, non-significant protection of n-3 was observed among statin non-users whereas statin users had no effect. Recent RCTs testing statins - after the implementation of the New Clinical Trial Regulation in 2007 - are negative (or flawed) suggesting that the lack of effect of n-3 cannot be attributed to a parallel protection by statins. Finally, statins favor the metabolism of omega-6 fatty acids (n-6), which in turn inhibits n-3 and, contrary to n-3, they increase insulin resistance and the risk of diabetes. Thus, n-3 and statins are counteractive at several levels and statins appear to inhibit n-3.
|Members of the public||30||63%|
|Practitioners (doctors, other healthcare professionals)||16||33%|
|Readers by professional status||Count||As %|
|Student > Bachelor||17||20%|
|Student > Master||13||15%|
|Student > Postgraduate||7||8%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||38||44%|
|Agricultural and Biological Sciences||10||11%|
|Biochemistry, Genetics and Molecular Biology||8||9%|
|Nursing and Health Professions||7||8%|